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Upper-left:  Human term placenta plastinated by Vasilis Sitras, exhibited at the Department of Human 
Anatomy, Faculty of Medicine, University of Tromsø. 
Upper-right:  Doppler blood flow velocity waveforms of the uterine artery with protodiastolic “notching” 
(arrow) indicating increased utero-placental vascular impedance. 
Lower-left:  Volcano-plot showing differentially expressed genes from a microarray experiment. The color 
indicates up-(red) or down- regulation (green). 
Lower-right:  Microscopic view of chorionic villus demonstrating laeverin immunofluorescence (green) in 
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Placenta has an important function of sustaining life in utero. Role of placental gene 
expression in the physiology of parturition and pathogenesis of pregnancy disorders are 
poorly understood. 
The aims of this thesis were to: 
1. Investigate the effect of labor on global gene expression profile of normal placentas  
2. Compare placental gene expression profile of uncomplicated pregnancies with that of 
pregnancies complicated by severe preeclampsia and intrauterine growth restriction 
(IUGR) 
Materials and Methods 
Hemodynamic assessment of the maternal uterine and feto-placental circulations was 
performed ≤72 hours before delivery using Doppler ultrasonography. Global gene expression 
profile was investigated using microarrays in placental samples collected after delivery from 
women with normal pregnancies (n=34), and pregnancies complicated by preeclampsia 
(n=16) and IUGR (n=8). The effect of parturition on gene expression was studied comparing 
placentas obtained from healthy women after normal delivery (n=17) with placentas obtained 
from women delivered by elective cesarean section (n=17). Placental gene expression profiles 
of women with severe preeclampsia (i.e. BP≥160/110 mmHg and proteinuria ≥2+ in dipstick) 
and IUGR due to placental insufficiency (i.e. estimated fetal weight <5th percentile for the 
gestational age with hemodynamic signs of redistribution of blood flow to the fetal brain) 
were compared with healthy controls. Microarray results were validated at the transcript and 
protein level by real-time reverse-transcriptase polymerase chain reaction (RT-PCR), 
placental immunofluorescence and urinary electrochemiluminescence immunoassay. 
Results 
Gene expression profile was similar in healthy placentas obtained following normal delivery 
and elective cesarean section.  Placental genes were differentially expressed in preeclampsia 
and IUGR compared to normal controls indicating a central role of the placenta in the 
pathogenesis of these pregnancy-specific disorders. In particular, 16 genes were able to 
differentiate preeclamptic from normal placentas in our samples after supervised clustering. 
Several known (leptin, Flt-1, endoglin) and some novel genes (laeverin) and pathways 
(angiogenesis, hypoxia, Alzheimer, Notch) were found to be involved in the pathogenesis of 




preeclamptic placentas showed different genetic signatures with oxidative stress, 
inflammation and endothelin signaling pathways mainly involved in early-onset disease.  
In IUGR, genes involved in glucocorticoid-metabolism and inflammation mediated by 
chemokine and cytokine signaling pathway were differentially expressed compared with 
controls. None of the known imprinted placental genes were differentially expressed.  
Conclusion 
Labor does not significantly alter the global gene expression profile in near term placenta. 
Placental gene expression profile is altered in severe preeclampsia and IUGR. Early-onset 
preeclampsia has a different genetic signature compared with late-onset preeclampsia 
supporting the possibility of different pathogeneses. Genes involved in inflammatory 
pathways are up-regulated both in early-onset preeclampsia as well as in IUGR, indicating 
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Evolutionary changes, starting 120 million years ago, led to the creation of placenta and the 
appearance of new species, the eutherian animals. Although the placenta has similar function 
in all species, different species developed placentas of unique structural complexity. Indeed, 
from a simple membrane in the inner surface of the egg in reptiles and birds, the placenta has 
evolved through several developmental steps to a complex organ in primates. These 
phylogenetic changes necessitated drastic reorganization of the morphological and molecular 
structure of the placenta, driven by mitochondrial and nuclear genetic rearrangement (Carter 
and Mess, 2007). Thus far, however, the molecular mechanisms behind this process are 
unknown. Even the developmental processes that occur in the placenta, from conception to 
birth, in a single species are still not completely clear. Recent longitudinal genomic studies in 
the murine placenta suggest that a transition occurs during mid-gestation, with usage of 
different genes by the same cellular populations, in the absence of any major morphological 
change (Knox and Baker, 2008). In the human placenta, developmental changes are thought 
to be controlled by different factors such as oxygen tension, placental hormones (hPL, hCG), 
growth factors (VEGF, PlGF) etc. Unbalanced regulation of these factors could lead to 
impaired placental development causing pregnancy complications such as miscarriage, 
preeclampsia and IUGR (Lyall and Kaufmann, 2000).  
 
1.1 Placenta: The organ of life 
Placenta is a temporary but essential organ in human development. It is highly vascular and 
mediates gas, nutrient and waste exchange between the fetal and maternal circulations. It is 
also an important endocrine organ that produces and metabolizes hormones in autocrine, 
paracrine and endocrine fashion, influencing its own function as well as that of the fetus and 
the mother. Additionally, the placenta seems to protect the fetus-allograft from the maternal 
immune system. One could argue that the placenta is a living organism itself as it undertakes 
some of the functions performed after birth by the lungs, gut, kidneys and endocrine organs. 
Indeed, mutations in genes involved in placental development and morphogenesis result in 
early fetal loss (Rossant and Cross, 2001).  
Recent, evolutionary morphologic analysis presents evidence that the human placenta 
has evolved from a common eutherian ancestor (Wildman et al., 2006).  From a morphologic 
point of view, placentas of different species can be divided in several types depending on the: 




tissue (iii) Feto-maternal interdigitation, which is the form of contact between maternal and 
fetal tissue/blood and (iii) Shape. The human placenta has: (i) Hemochorial interface, because 
trophoblastic cells are highly invasive and penetrate in the maternal spiral arteries. (ii) Villous 
interdigitation and (iii) Discoid shape.  
The human placenta undergoes a continuous remodeling throughout the pregnancy in 
response to changing functional needs. Formation of the placenta starts after the union 
between a sperm and an egg (fertilization) forming the embryo, which undergoes mitotic 
divisions to form the blastocyst. This has two different cell populations: the inner cell mass 
which develops in the embryo proper and the trophectoderm from which the placenta and the 
extraembryonic membranes are formed. Already at this early stage, during implantation of the 
blastocyst in the decidua (i.e. the uterine epithelium during pregnancy), the trophectoderm is 
responsible for the interconnection of the developing embryo with the mother and thus plays a 
crucial role in the successful outcome of pregnancy (Dey et al., 2004). Development of the 
placental villi, the functional units of the placenta, starts when cytotrophoblast proliferation 
gives rise to branches that protrude into the lacunae containing maternal blood to form the 
villous tree (primary villi). At 5 weeks gestation these villi are invaded centrally by extra-
embryonic mesenchyma, transforming into secondary villi. During the second trimester, feto-
placental capillaries are formed de novo (vasculogenesis) in the central stroma of the villi, 
transforming them into tertiary villi which have several branches and sub-branches with 
blunt-ended extremities that form the “villous tree”. 
At term, the feto-maternal hemochorial interface provides a surface of 15 m2 for 
exchange and consists of five distinct layers: (i) Villous syncytiotrophoblast lining directly the 
intervillous space which bathes in maternal blood (ii) Basal membrane (iii) Villous core 
containing extracellular matrix and pericytes (iv) Basement membrane attached to capillary 
endothelial cells and (v) Fetal capillary endothelial cells where fetal blood circulates 
(Georgiades et al., 2002). 
 
1.2 Feto-placental-maternal circulation 
In the 16th and 17th century, Aranzio and William Harvey described that the uterine and 
umbilical vessels are not directly connected in the placenta and that fetal blood is circulated 
within fetal tissues and to some extent into the placenta (Fishman and Richards, 1964). The 
driving force directing blood in the placenta is probably the pressure gradient between the two 





During embryogenesis, hematopoiesis  occurs within the yolk-sac (Pereda and Niimi, 
2008) and within the villous capillaries from hematopoietic stem cells (Demir et al., 1989). 
The feto-placental circulation is established by seven weeks of gestation. Morphological 
studies have demonstrated continuous evolution of the different villous types during gestation 
(Kaufmann et al., 1979). In the first and second trimester, trophoblastic sprouts generate new 
mesenchymal villi that transform into poorly vascularised immature intermediate villi causing 
high placental vascular impedance (Fisk et al., 1988). In the third trimester, mesenchymal villi 
transform to mature intermediate villi, which don’t self-replicate but elongate and produce 
terminal villi. The decrease in trophoblast proliferation along with a relative increase in 
endothelial proliferation from 26 weeks of gestation until term causes a switch from 
branching to non-branching angiogenesis (i.e. formation and differentiation of new blood 
vessels). This results in the formation of long and slender villous trees containing one or two 
poorly branched capillary loops, which in turn, cause a decrease in feto-placental vascular 
impedance (Jauniaux et al., 1992). These morphological changes in villous tree development 
are reflected in the hemodynamic changes observed in the feto-placental circulation 
throughout pregnancy. Indeed, ultrasound assessment of the feto-placental circulation shows a 
gradual increase in the fraction of  the fetal cardiac output distributed to the placenta in the 
second trimester (Vimpeli et al., 2008) with slight decrease towards term (Kiserud et al., 
2006).   
The maternal side of the placenta is perfused ~ 83% by the two uterine arteries and 
~17% by the ovarian arteries (Wehrenberg et al., 1977), and about 75% of the uterine flow 
circulates in the intervillous space (Bartels and Moll, 1962). There is a steady increase in 
uterine blood flow with advancing gestation (Thaler et al., 1990), although the uterine blood 
flow normalized by fetal weight decreases (Konje et al., 2001). There is an increase in blood 
flow in the common iliac artery, but the blood flow in the external iliac artery decreases, 
indicating redistribution of lower extremity blood flow to the pregnant uterus and the placenta 
(Palmer et al., 1992). Clearly, a carefully orchestrated and balanced maturation of the feto-
placental and utero-placental circulations is necessary for the physiologic function of the 
placenta, which is reflected in fetal and maternal wellbeing throughout gestation (Kingdom 
and Kaufmann, 1997). However, maternal uterine artery blood flow and oxygen delivery to 
the placenta, are not the sole determinants of fetal wellbeing. Indeed, a recent study on 
maternal oxygen transport in relation to fetal growth in high altitude pregnancies of two 
genetically different populations, concluded that the largest independent determinant of fetal 




placenta might play an essential role not only in determining pregnancy outcome, but also in 
the development of disease in adult life (Giussani, 2007). 
 
1.3 Gene expression 
The expression of deoxyribonucleic acid (DNA) follows the rules of a central dogma which 
occurs in two stages: (i) Transcription, during which DNA is transcribed into messenger RNA 
(mRNA) and (ii) Translation, during which mRNA serves as a template for protein synthesis.  
The term gene expression refers to the process of decoding the DNA information, from 
gene to protein. The expression level of different genes among cells or tissues varies 
depending on the function, developmental stage or disease state, resulting in different 
phenotypes (i.e. the observable properties of an organism that are produced by the interaction 
of the genotype and the environment). Regulation of gene expression is complex, but 
schematically it can be divided in four different levels as shown in Figure 1: The first and 
most important level is transcription initiation. The next is maturation of pre-mRNA to 
mRNA by alternative splicing [removal of non-protein coding DNA sequences (introns) and 
putting together coding sequences (exons)]. Further regulation of gene expression occurs at 
the translation level, through mRNA editing, and finally, at the protein level through post-
translational modifications that can determine protein activity. Recently, approximately 700 
human small-RNAs (consisting of 20-30 nucleotides) have been shown to play an important 
role in gene expression (Kim et al., 2009) by interfering with chromatin formation, mRNA 



















2. AIMS OF THE THESIS 
The main aim of this thesis was to investigate the global gene expression profile in healthy 
and compromised human placentas. More specific objectives were to study the effect of: 
 a) normal labor, b) severe preeclampsia, and c) IUGR due to placental insufficiency on global 
placental gene expression profile.  
Additional aims were to investigate the differences in placental gene expression profiles 
between early- and late-onset preeclampsia, and between IUGR with and without 
preeclampsia. 
 
3. MATERIALS & METHODS 
3.1 Study population 
Pregnant women were recruited from the Department of Obstetrics and Gynecology, 
University Hospital of Northern Norway, during the period January 2005 - November 2006. 
The study protocol was approved by the Regional Committee for Medical Research Ethics 
(REK-Nord 94/2004). A total of 79 pregnant Caucasian women were recruited to the study. 
Informed written consent was obtained from all the participants. The flow of participants is 
shown in Figure 2. 
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Gestational age was assigned by ultrasound at 18-20 weeks gestation. Severe 
preeclampsia was defined as a  blood pressure (BP) of at least 160 mmHg systolic and/or 110 
mmHg diastolic, with proteinuria  ≥2+ on dipstick, measured on at least two occasions 6 
hours apart while the patient was on bed rest, or hemolysis, elevated liver enzymes and low 
platelet (HELLP) syndrome, after the 20th week of gestation (Sibai et al., 2005). Women with 
pre-existing chronic hypertension, renal disease, lupus erythematosus, diabetes, and 
gestational hypertension without proteinuria were excluded. IUGR was defined as: (i) birth 
weight below the 5th percentile for the gestational age according to Norwegian nomograms 
(Skjaerven et al., 2000) (ii) oligohydramnios (i.e. amniotic fluid index ≤5th percentile for the 
gestational age) in the absence of fetal congenital urinary tract abnormality (Phelan et al., 
1987) and (iii) abnormal fetal Doppler parameters (absent or reversed end-diastolic flow in 
the umbilical artery or signs of blood flow redistribution to the fetal brain, i.e. middle cerebral 
artery pulsatility index (PI) <5th percentile and umbilical artery PI >95th percentile). Women 
with small for gestational age fetuses with normal Doppler, known fetal chromosomal or 
structural congenital abnormality or infection were excluded. 
Physical examination and ultrasonography were performed and blood and urinary 
samples were collected ≤72 hours before delivery. Placental and cord blood samples were 
collected immediately after delivery, following a standardized technique by two designated 
persons. Blood samples from the umbilical artery and vein were separately analyzed for acid-
base status using a spectrophotometer ABL 725 Blood Gas Analyzer (Radiometer Medical 
AS, Copenhagen, Denmark) within 15 minutes of collection. Samples that had a pCO2 
difference of <1 kPa (7.5 mmHg) and pH difference of <0.03 units between umbilical arterial 
and venous blood were considered to have mixed blood and were discarded. The neonatal and 
placental weights were determined using electronic scales (Seca Model 727, Vogel & Halke, 
Hamburg, Germany). Outcome of pregnancy and information on the neonates were 






Figure 3. Microsoft Access data file showing the list of variables recorded for each participant of the study 
 
3.2 Hemodynamics 
Maternal uterine and feto-placental hemodynamics was studied using Acuson Sequoia 512 
ultrasound system (Mountain view, CA, USA) with a 2.5 - 6 MHz curvilinear transducer. 
After a survey of fetal anatomy, biometry was performed to estimate the fetal weight. Blood 
flow velocity waveforms were obtained from the maternal uterine arteries, fetal middle 
cerebral artery, and umbilical artery and vein at a free-loop of the cord using color directed 
pulsed-wave Doppler. A large sample volume (5-10mm) and lowest possible insonation angle 
(kept below 20 degrees) were used. Velocity measurements were performed online and angle 
correction was used as required. Values used for statistics were an average of at least three 
cardiac cycles. The PI was calculated from the arterial blood velocity waveforms as:  
PI = (peak systolic velocity − end-diastolic velocity)/time-averaged maximum velocity 
Umbilical vein inner diameter was measured at a free-loop of the cord using B-mode 
ultrasound. Uterine artery diameter was measured using power Doppler angiography 
(Acharya et al., 2007; Konje et al., 2001). The values used for analysis were an average of 




arteries were calculated as the product of time-averaged intensity weighted mean velocity 
(Vmean) and the cross-sectional area (CSA) of the blood vessel: 
Q (ml/min) = Vmean (cm/s) * CSA (cm2)* 60 
Assuming that the blood vessel has a circular lumen, CSA was calculated as:  
CSA = π * Radius2 = 0.785*Diameter2  
 
3.3 Microarrays 
The founding report on microarray technique was based on the genome of the flowering plant 
Arabidopsis thaliana containing the smallest genome of any higher eukaryote examined to 
date (Schena et al., 1995). It was a pioneering study demonstrating a novel high-capacity 
system that could monitor the expression of 45 genes in parallel. Although recent advances in 
sequencing and microarray technology have produced high-density microarrays, the basic 
methodology of DNA microarray remains similar: RNA samples or targets are hybridized to 
known cDNAs/oligo probes on the arrays. One such sequencing effort is the Human Genome 
Project. It was established as an international project with the aim to identify the 
chromosomal position and genomic organization of all human genes. In 2004, the 
International Human Genome Sequencing Consortium completed 99% of the human DNA 
sequencing and announced that “the human genome could be regarded as effectively known” 
(IHGSC, 2004).  
A microarray is a small (approximately 1.3x1.3 cm) glass, silicon slide or chip upon 
the surface of which a large number of known human gene sequences (usually from 500 to 
35 000) are fixed in defined positions in a matrix-fashion. There are two types of microarrays: 
(i) cDNA microarrays where individual DNA sequences are spotted on the array (usually up 
to 1500 base pairs) (ii) Oligonucleotide-arrays where oligonucleotides (usually 70-mers) are 
either printed or robotically synthesized directly on the array. Microarray technology offers 
the potential to analyze the expression state of each individual gene represented in the genome 
in a single experiment. Yet, with this method it is impossible to quantify the absolute 
expression level of a gene. It is thus necessary to perform comparative studies, for example 
normal versus diseased tissue samples, in order to obtain the relative gene expression profile 
of a given sample. A typical microarray experiment is executed following a number of 




















Figure 4. Outline of a typical microarray experiment 
 
Experimental design 
The first and most crucial step of microarray experiments is the design (Yang and Speed, 
2002) which is dependent on the aim of the study. Microarray studies are comparative studies 
and the overall results depend on the phenotypic characteristics of the samples that are 
compared. Gene expression profiling of a diseased sample, is based on the relative up- or 
down-regulation of each gene, compared to an “assumed” healthy sample which is used as 
control. Possible confounding factors that would add “noise” to the data should also be taken 
into account. Given that y represents a measurement of gene expression in the placenta, the 
following linear model may be calculated: 
y = parity + maternal age + delivery method +  … + healthy or diseased + ε 
where ε is an “error-term” representing the inherent biological variation of the sample and the 
measurement error of the system. 
There are three main types of experimental design: (i) Direct, where each diseased 
sample is matched to one healthy control (pair-wise comparison), (ii) Indirect, where each 
diseased sample is matched to a pool of several healthy samples (common reference) and (iii) 

















Figure 5. Graphical representation of microarray experimental designs. The arrows indicate hybridization 
between two mRNA samples (A, B, C etc) 
  
Microarray laboratory procedures 
There are five laboratory steps during a microarray experiment: 
1. RNA extraction and quantity/quality control  
2. Labeling  
3. Hybridization  
4. Washing  
5. Image acquisition 
 
RNA extraction and quantity/quality control 
Disruption and homogenization of placental samples were performed in lysis buffer using the 
MagNa Lyser Instrument (Roche Applied Science, Germany), according to the 
manufacturer’s instructions. Isolation of total RNA was performed using the MagNa Pure 
Compact RNA isolation kit and the MagNa Pure Compact Instrument (Roche Applied 
Science, Germany) (Paulssen et al., 2006). RNA was quantified by measuring absorbance at 
260nm, and RNA purity was determined by the ratios OD260nm/280nm and 
OD230nm/280nm using the NanoDrop instrument (NanoDrop® ND-1000, Wilmington, 
USA). The RNA integrity was determined by electrophoresis using the Agilent 2100 
Bioanalyser (Matriks, Norway). Only RNA samples with a ribosomal RNA 28S/18S ratio of 
>1 and/or RNA Integrity Number >7.2 were used for microarray experiments (Schroeder et 




Two different microarray platforms were used for the studies of this thesis: (i) A two-
channel platform, needing two fluorescent dyes (direct labeling) in study I and a one-channel 
platform, based on chemiluminescence (indirect labeling), in studies II and III.  
 
Microarray procedures for study I  
For the two-channel platform, total RNA was reverse transcribed and labeled directly with 
Cy3- and Cy5- attached dendrimer (Figure 6), using the Genisphere 3DNA 350HS kit 
(Genisphere, Montvale, NJ) as described in the manufacturer’s protocol. Hybridizations were 
carried out in a TECAN HS4800 instrument (TECAN, Austria) using the formamide-based 
hybridization buffer from Genisphere containing 5% dextrane sulphate and 5.5 ng/ml human 
COT1-DNA (GIBCO-BRL Life technologies) at 37º for 23 hours. 3DNA dendrimer 
hybridizations were carried out in formamide-based hybridization buffer alone. Post-
hybridization washes were carried out at room temperature with 2x saline sodiumcitrate 
(SSC) for 1 min, 0.2% sodium dodecylsulphate (SDS) /2xSSC  for 1 min and finally with 
0.2xSSC for 30 sec. For global gene expression analysis 35K oligo microarrays were used 
that were obtained from the Norwegian Microarray Consortium (http://www.microarray.no). 
Briefly, the arrays contained spotted 70-mer oligonucleotides obtained from the Human 
Array-Ready Oligo Sets (AROS™) v3.0, OPERON, Germany (http://www.operon.com). The 
set contained 34,580 probes representing 24,650 human genes and 37,123 gene transcripts. 
The probe design is fully based on the Ensembl Human 13.31 Database 
(http://www.ensembl.org) and Human Genome Sequencing Project. As external control 
system, the Spot Report oligo validation system (Cat# 252170-7) from Stratagene was used. 





Figure 6. Flowchart describing the microarray experiment for study I 
 
Microarray procedures for studies II and III 
For the one-channel platform, total RNA samples were processed into digoxigenin (DIG)-
labeled cRNA (Figure 7) using the Applied Biosystems Chemiluminescent NanoAmp™ RT-
IVT Labeling Kit. The labeled DIG-cRNA (10 μg per microarray) was then injected into each 
microarray hybridization chamber. Following hybridization at 55°C for 16 hours, the unbound 
material was washed from the microarrays. Features that retained bound DIG- labeled cRNA 
were visualized using the Applied Biosystems Chemiluniescence Detection Kit. Anti-DIG 
alkaline phosphatase was used to hydrolyse a chemiluminescence substrate to generate light at 
458nm which was than detected by the Applied Biosystems 1700 Chemiluninescent 
Microarray Analyzer. The Human Genome Survey Microarray v.2.0 (Applied Biosystems) 






Figure 7. Flowchart describing the microarray experiments for studies II and III 
 
Image analysis 
The scanned images are then turned into numbers, called raw data. Each spot on the 
microarray is given a number depending on its fluorescence intensity. The main steps during 
image analysis are normalization, aiming to remove effects from the technical process from 
the data (for example different labeling efficiencies, different scanning parameters etc), and 
filtering aiming to eliminate spots that will bias or add noise to the results. 
In study I, the features were extracted from the arrays using Genepix 6.0 software 
(Axon instruments Inc., 2004). The background estimates were calculated using the 
morphological opening method (Soille, 2006). Spots that displayed a signal-to-noise ratio of 
less than three or that were significantly saturated (more than 20% saturation among 
foreground pixels) were filtered out. The median was used as the averaging measure of the 
foreground pixels.  After quality control, genes that were present in less than 50% of the 
arrays were filtered out. Normalization was carried out using Lowess normalization 
(Cleveland, 1979). 
In study II, the features were extracted from the arrays using the ABI1700 software. 
Normalization was carried out using quantile normalization which forces all the slides to have 




expression values missing for ≥25% of the samples in the preeclampsia group or ≥35% in the 
control group were filtered out.  
In study III, the features were extracted from the arrays using the ABI1700 software. 
The gene expression data were analyzed using J-Express pro 2.7 (Molmine, Bergen, Norway) 
(Dysvik and Jonassen, 2001). The pre-normalized intensity values were extracted per spot 
from the data files. Weak spots with signal to noise ratio <3.0 and control spots were filtered 
out. All arrays were normalized by the Lowess method (Cleveland, 1979). Missing expression 
levels were inferred using the LSimpute method (Bo et al., 2004). 
 
Data analysis  
Microarray experiments generate large amount of data and represent a challenge for 
conventional statistical methods. Novel computational methods that are able to handle large 
datasets are developed. A major problem in microarray experiments is the abundance of false 
positive findings and often adjustment with multiple testing and permutation (i.e. reordering) 
of the data is necessary in order to reduce type I errors (false positives). Microarray data 
analysis aims to find genes with different fluorescent intensity between arrays, i.e. 
differentially expressed genes between distinct phenotypic groups. A gene is differentially 
expressed between two groups when it is systematically up- or down-regulated in one group 
compared to the other. Differentially expressed genes are usually presented at two levels: (i) 
statistical level shown by p-values indicating the probability that the difference in gene 
expression of a particular gene between two samples is true and (ii) biological level which is 
the mean fold-change in relative over- or under-expression of a particular gene between the 
samples. The level of p-value and fold-change above which the genes are “significantly” 
differentially expressed is arbitrary. In addition, clustering methods and principal component 
analysis (PCA) (Raychaunhuri et al., 2000) that organize genes or samples into groups or 
hierarchy based on expression similarity are used in order to make microarray results easier to 
understand.   
 More specifically, for the purpose of finding differentially expressed genes in study I, 
we applied an empirical Bayes analysis (Smyth, 2004) using the LIMMA package (Smyth, 
2000). The data were analyzed using a two-component linear model. The prior guess of the 
number of differentially expressed genes was set to 0.01. Multiple testing was accounted for 
by estimating the false discovery rate (set at <15-20%) applying the Benjamini-Hochberg  
(Benjamini, 1995) and Storeys less conservative Q-value (Storey, 2002) procedure. A 2.5-fold 




the difference in fluorescence intensity between two matched samples reached a p-value of < 
0.01. 
For the purpose of finding differentially expressed genes in study II, we applied an 
empirical Bayes analysis using the LIMMA package. The data were analyzed using an 
ANOVA two-component linear model accounting for preeclampsia versus normal and 
nulliparity versus multiparity. We further used the same method in order to identify potential 
differentially expressed genes between early- and late-onset preeclampsia. The cut-off time-
point of early- versus late-onset preeclampsia was 34 weeks gestation. The prior guess of the 
proportion of differentially expressed genes was set to 0.01. A two-fold change in expression 
of any gene was considered significant, if the difference in fluorescence intensity between the 
samples reached a p-value < 0.01. A hierarchical cluster analysis was conducted on the 300 
most differentially expressed genes. A Predictive Analysis of Microarrays (PAM) (Tibshirani 
et al., 2002) was conducted in order to investigate whether any set of genes provides 
predictive power between the groups (preeclampsia versus normal). 
In study III, statistical significance was assigned to the genes by using the Significance 
Analysis of Microarrays (SAM) methodology (Tusher et al., 2001). PCA was performed on 
the 20 genes with best t-scores in the main analysis, in order to obtain discrimination between 
IUGR and normal placentas. 
 
Database submission of microarray data 
The Microarray Gene Expression Data Society (MGED; http://www.mged.org) has 
recommended that all publications using microarray technology should be compliant with the 
MIAME (Minimal Information About Microarray Experiments) requirements (Brazma et al., 
2001) and raw data should be available in public repositories such as ArrayExpress (Brazma 
et al., 2003) or Gene Expression Omnibus (GEO)(Edgar et al., 2002). All our studies are 
MIAME compliant and raw data can be retrieved in GEO 
(http://www.ncbi.nlm.nih.gov/projects/geo/) with accession numbers GSE 8375, GSE 10588 
and GSE 12216 for study I, II and III respectively. 
 
Gene Annotations 
The last step of microarray studies is the interpretation of the results. Lists of differentially 
expressed genes between groups are examined in order to find possible 
associations/interactions regarding their biological function (cellular events to which the gene 




biochemical level) or pathways (molecular signaling networks of communication between 
genes/proteins).  This process is performed via internet-databases with updated, evidence-
based information/knowledge on gene/protein function by using software able to handle large 
datasets. In other words, the ultimate scope of every microarray experiment is to find answers 
on biological questions such as: What is the role of the differentially expressed genes in 
determining the disease phenotype? Which cellular/molecular pathways might be involved? 
How does the disease process affect cellular/tissue function and phenotype? Or vice versa, 
how does cell/tissue remodeling affect pathogenesis of disease? Are there single genes or sets 
of genes that could predict disease severity and outcome; and if so, through which pathways? 
Ultimately, could the findings be applied in clinical practice?   
For the annotation of the genes, PubGene 2.6™ Database and Analysis Software 
(Jenssen et al., 2001) and DAVID Bioinformatics Resources 2007 (Dennis et al., 2003) were 
used in study I and Protein ANalysis THrough Evolutionary Relationships (PANTHER) (Mi 
et al., 2007) in studies II and III. 
 
3.4 Real-time reverse-transcriptase polymerase chain reaction  
As a large amount of genes might be differentially expressed in microarray experiments, the 
level of expression of selected genes must be confirmed by other independent methods.  
RT-PCR is the method of choice to validate microarray data. It was invented by Kary 
Mullis (Mullis, 1990) and is a method for amplifying a specific region of a DNA strand, by 
mimicking the DNA duplication process occurring in nature. The process requires a DNA-
template, one or more specific primers, two enzymes (reverse transcriptase and DNA 
polymerase) and several deoxynucleotide triphosphates that serve as “bricks” to build a new, 
complementary DNA strand (cDNA). The process consists of three steps: (i) Reverse 
transcription and denaturation from single stranded DNA-template to cDNA (ii) Primer 
annealing and (iii) Primer extension (elongation) with formation of cDNA. This procedure is 
repeated several times, in general 20-35 cycles, so that the amount of cDNA increases 
exponentially (Freeman et al., 1999).  
In RT-PCR there is an additional fourth step during which a fluorogenic probe is 
annealed to the cDNA sequence, between the forward and reverse PCR primers. During 
extension the fluorescent molecule is cleaved, emitting fluorescence that is measured 







Figure 8. Outline of RT-PCT technique, reproduced with permission from King and Sinha, JAMA, 2001 
 
An example of an RT-PCR amplification curve of a gene (MML3) is shown in Figure 
9. The curves indicate the fluorescent signal of the PCR product (ΔRn) at each time point, 
reaching an exponential phase where there is a doubling of the product with each cycle. The 
higher the starting copy number of the gene, the earlier the exponential phase starts. A fixed 
fluorescence threshold is set by the operator, significantly above the baseline (red line). A 
parameter called CT (threshold cycle) is defined as the cycle number at which the fluorescence 







Figure 9. Example of RT-PCR amplification curve of a gene (MML3) 
 
In RT-PCR the relative expression of a gene is normalized to genes that are 
constitutively active, called housekeeping genes. These genes have a constant expression 
regardless of the state of the cell. There are several housekeeping genes in the human placenta 
(Vandesompele et al., 2002; Meller et al., 2005). By comparing the CT values of the genes in 
question with the CT values of housekeeping genes, one can calculate the expression level of 
the genes in different states of the samples, by using different formulas (Livak and 
Schmittgen, 2001; Pfaffl, 2001).  
 
3.5 Placental morphology 
All placentas were macroscopically examined in the labor ward after delivery for 
completeness, number of umbilical cord vessels, color of the membranes and gross 
morphology of the maternal surface looking for signs of retroplacental clots, calcifications, 
infarctions etc. After taking biopsies, whole placenta was immersed in 4% formalin and sent 
for histopathologic examination. All placentas were examined according to our hospital’s 
standard laboratory procedure. Five sections were examined that were sampled from the 
umbilical cord, membranes, central portion of placenta, basal plate and transmural central 
part, respectively. One pathologist with special training in placental microscopy, evaluated all 
sections of the preeclamptic placentas, without prior knowledge of clinical status, looking for 
signs of inflammation as described previously (Redman et al., 1999) in standard hematoxylin 





3.6 Urinary human chorionic gonadotropin measurement 
Urinary samples were collected from the mother before delivery and stored at –70°C until 
further analysis. Urinary hCG concentration was measured in 41 normal pregnancies and 18 
pregnancies affected by severe preeclampsia by an automated electrochemiluminescence 
immunoassay method using intact hCG + β-subunit kit (Modular E170 Analyser, Roche 
Diagnostics) which has previously been validated (Ajubi et al., 2005). 
 
3.7 Leptin immunofluorescence 
Tissue sections were fixed in formalin and embedded in paraffin blocks according to standard 
procedures. Glass slides were cleaned with 95% ethanol, treated with subbing solution and air 
dried. 4–6 micron thick tissue sections were cut and applied to slides. Slides were 
deparaffinized in xylene using three changes 5 minutes each. Sections were hydrated 
gradually through graded alcohols (100% ethanol twice for 10 minutes each, then 95% 
ethanol twice for 10 minutes each). Slides were then washed in de-ionized water for 1 minute 
with stirring and excess liquid aspirated from slides.  
Antigen unmasking was performed using heat treatment. Slides were placed in a 
prewarmed solution of 10 mM sodium citrate buffer, pH 6.0 for 5 min. This step was repeated 
once. Slides were let to cool down at room temperature in the buffer for 20 minutes before 
they were washed in de-ionized water three times for 2 minutes each and excess liquid was 
aspirated from slides.  
Slides were incubated with 500 µl 10% normal goat blocking serum (Santa Cruz 
Biotechnology, Inc, USA) in 1x phosphate buffered saline (PBS) for 20 minutes at room 
temperature. Suction was used to remove reagents (drying of the specimens was avoided 
between steps) before slides were washed in 1xPBS two times for 2 minutes each. Primary 
antibody for leptin 2.5 µg/ml (Ob (A-20) Santa Cruz Biotechnology, Inc, USA) in PBS with 
1.5% normal blocking serum was incubated for 60 minutes. PBS only was used to test the 
specificity of the primary antibody (negative control). Slides were washed with three changes 
of PBS for 5 minutes each and then incubated for 45 minutes at room temperature with 
secondary goat anti-rabbit IgG-FITC 2.5 µg /ml (Santa Cruz Biotechnology, Inc, USA) in 
PBS with 1.5% normal blocking serum. Slides were washed with three changes of PBS for 2 
minutes each before they were air dried and counterstained with DAPI (4’,6-diamidino-2-
phenylindole) II (Vysis, Abbott Diagnostics, USA).Images were obtained using a CytoVision 
(Applied Imaging, San Jose, CA, USA) digital system equipped with a charged-coupled 




4. MAIN RESULTS 
4.1 Paper I 
Gene expression profiling was carried out on mRNA extracted from placental samples that 
were obtained from 17 women after vaginal delivery (laboring) and 17 women after elective 
cesarean section before the onset of labor (non-laboring). All women were healthy and had 
uncomplicated pregnancies. There were no significant differences regarding maternal 
phenotype, hemodynamic parameters and pregnancy outcome between the groups. In the 
group of women delivering vaginally, the mean duration of labor was 7.6 (range, 2-15) hours. 
Out of approximately 25 000 genes that were represented on the array, one third (n=8000) 
passed stringent quality criteria. An empirical Bayes analysis was performed in order to find 
differentially expressed genes. Only three genes, namely FOS, FOSB and GNGT1 were 
differentially expressed more than 2-fold. Several other genes captured by microarrays were 
related to oxytocin degradation (LRAP) and placental hormone metabolism (HSD17B4), but 
did not seem to be significantly affected by the mode of delivery.  Furthermore, validation 
using RT-PCR (Paper I, Table 2) showed only FOS to be actually down-regulated by 2.2 
mean fold-change in laboring compared to non-laboring placentas (Figure 9), suggesting that 














Figure 10. Relative expression of FOS normalized for SDHA (housekeeping gene) in for each of the placental 
samples estimated by RT-PCR. Red indicates laboring, green indicates non-laboring placentas; mean 







4.2 Paper II 
Gene expression profiling was carried out on mRNA extracted from placental samples that 
were obtained from 21 women with severe preeclampsia and from 21 controls that were 
randomly selected from a group of 50 women with uncomplicated pregnancies. Preeclamptic 
women had an average mean arterial pressure of 132mmHg and proteinuria of 5g in a 24-hour 
urine specimen. They were not significantly different in terms of age, parity and body mass 
index (BMI) from their controls. However, they had significantly higher mean uterine artery 
PI and reduced uterine artery volume blood flow, although the fetal circulation was not 
compromised as indicated by normal cerebro-placental ratio (middle cerebral PI/umbilical 
artery PI) and normalized umbilical vein volume blood flow. Eleven out of sixteen 
preeclamptic women were delivered prematurely (at <37 weeks) by cesarean section before 
the onset of labor and among them 3 had HELLP syndrome. The method of delivery (vaginal 
versus cesarean) was balanced between the groups. The number of small for gestational age 
babies was significantly higher and placental weight lower among preeclamptic women 
compared with controls. Two preeclamptic women had growth restricted fetuses. However, 
the neonatal outcome was not different between the groups.  
After RNA isolation, five preeclamptic placentas were excluded due to poor RNA 
quality. Thirty-seven hybridizations in a one-channel detection system of chemiluminescence 
emitted by the microarrays were performed. A total of 18811 genes on the arrays passed our 
quality criteria after image analysis. In preeclamptic placentas 213 genes were significantly 
(fold-change≥2 and p≤0.01) up-regulated and 82 were down-regulated, compared with normal 
placentas (Paper II, Table 1S). Supervised clustering analysis showed 16 of these genes able 
to differentiate preeclamptic from healthy placentas (Paper II, Figure 1). Microarray results 
were validated by RT-PCR for 16 selected genes and there was a good correlation for most of 
them (Paper II, Table 3S). Different subtypes of hCG were up-regulated in preeclamptic 
placentas from 3.5 to 6.4 fold. We validated this result by measuring hCG concentration in 
maternal urine. Mean concentration of urinary hCG in the control group was 20034 (95% CI: 
13121-27687) IU/L and in preeclamptic patients 68271 (95% CI: 18917-117624) IU/L 
(p=0.04). There was no significant correlation between urinary hCG values and placental 
weight (r=0.03; p=0.823). Leptin RNA was highly (40 fold) up-regulated in the preeclamptic 
placentas both in microarray and RT-PCR. In order to correlate this result with leptin protein 
expression levels, immunofluorescence was performed in preeclamptic and normal placentas. 
Leptin was expressed in the villous trophoblast and was more abundant in the preeclamptic 




Pathway analysis using all differentially expressed genes between 16 preeclamptic and 
21 normal placentas showed several differentially expressed genes to be associated with 
Alzheimer disease, angiogenesis, Notch-, TGFβ- and VEGF-signaling pathways. Preliminary 
biological link analysis showed that hypoxia, apoptosis, angiogenesis and folate metabolism 
were altered in the preeclamptic placentas (data not shown).  
The preeclamptic placentas were further sub-grouped depending on (i) disease onset 
and (ii) level of proteinuria.  
Five placentas were delivered before 34 weeks of gestation (early-onset preeclampsia) 
and 11 after 34 weeks (late-onset preeclampsia). Microarray data analysis showed 402 
differentially expressed genes between these groups (Paper II, table 2S and Figure 2). 
Comparison of pathways showed that oxidative stress, inflammation mediated by chemokine 
and cytokine and endothelin signaling pathways were mainly involved in early-onset 
preeclampsia (Paper II, Figure3). This result was validated for selected genes by RT-PCR 
(Paper II, Table 3S).  
Preeclamptic placentas were stratified in three different phenotypes, according to the 
level of proteinuria: Group A: four patients with proteinuria 1-2 g/l, Group B: five patients 
with proteinuria 3-4 g/l and Group C: five patients with proteinuria ≥ 5 g/l.  A three-
component ANOVA was performed that showed significant differences in gene expression 






Figure 11. Volcano plot showing differentially expressed placental genes between preeclamptic women 
with proteinuria 1-2 g/l compared to those with proteinuria >5 g/l. Each spot represents a gene and color 
intensity represents the expression level. All the genes located on the upper-lateral quadrants are 




4.3 Paper III 
Gene expression profiling was carried out on mRNA extracted from placental samples that 
were obtained from eight patients with IUGR due to placental insufficiency, and from eight 
women with uncomplicated pregnancies that served as controls. Four women with IUGR also 
had preeclampsia. There were no significant differences regarding maternal age, parity and 
weight gain during pregnancy between the groups. Gestational age, birth weight and placental 
weight were significantly lower in IUGR pregnancies. All patients with IUGR had 
oligohydramnios and hemodynamic signs of redistribution of blood flow to the fetal brain, as 
implicated by the inclusion criteria of the study. Two women in the IUGR group received a 
single course of antenatal corticosteroid. The mode of delivery (vaginal versus cesarean) was 
balanced between the study groups. Neonatal outcome was favorable in both groups as 
indicated by Apgar scores and cord blood acid-base status (Paper III, Table 1). 
Microarray data analysis showed that in IUGR placentas 47 genes were up-regulated 
and 70 genes were down-regulated at a significant level (fold-change ≥1.5 and p-value≤.05) 
compared with normal placentas (Paper III, Tables 2 and 3). PCA for the top 20 differentially 
expressed genes showed good separation in terms of gene expression patterns between the 
groups (Paper III, Figure 1). Pathway analysis of differentially expressed genes between 
IUGR and normal placentas, after Bonferroni correction for multiple testing, showed 
significant up-regulation of the inflammation mediated by chemokine and cytokine signaling 
pathway (pathway accession number P00031 in http://www.pantherdb.org). Subgroup 
analysis comparing IUGR with and without preeclampsia showed few (n=27) differentially 
expressed placental genes (Paper III, Table 4). Validation of the microarray results by RT-
















This thesis recapitulates three studies on global gene expression profile of healthy (laboring 
and non-laboring) and compromised (preeclamptic and IUGR) placentas using genome wide 
microarrays. Placental gene expression was altered by disease states but not by normal labor. 
Results have been validated at the transcript and protein levels for selected genes. These 
results indicate that gene expression profiling of the human placenta is a useful tool in the 
effort to understand the role of the placenta in parturition and in the patho-physiology of 
pregnancy-specific disorders, such as preeclampsia and IUGR. 
 
5. 1 Gene expression profile of the normal placenta  
The human placenta is a complex tissue composed by a broad variety of placental/fetal and 
maternal cells. Structural heterogeneity of placental villi depends mainly on the degree of 
maturity and on the sampling site of the placenta. Accordingly, global gene expression profile 
varies within the normal placenta (Sood et al., 2006). In particular, it appears that hypoxia-
related genes are up-regulated in placental sites distant to the umbilical cord insertion and 
towards the basal and chorionic plates (Wyatt et al., 2005), possibly reflecting reduced blood 
perfusion at these sites (Matijevic et al., 1995). In fact, these changes in gene expression, 
although modest (up to three-fold), correlate well with villous histology, i.e. increased fibrin 
deposition and syncitial knots and reduced villous size, mostly observed at the periphery of 
the placental disc. Moreover, gene expression profiling of the feto-maternal interface (basal 
plate) between midgestation and term, showed dramatic changes regarding angiogenesis, cell 
motility, extracellular matrix modulation, gene transcription, signal transduction, immune 
response, protein biosynthesis, and lipid metabolism (Winn et al., 2007). Therefore, for the 
purpose of this thesis, placental samples were taken from a standardized location, 
approximately 2cm beside the umbilical cord insertion (a landmark that is easily 
recognizable), and the sample included tissue from the middle layer of placenta midway 
between maternal and fetal surfaces. This is a representative site to study placental gene 
expression as it includes central villous parenchyma that is well perfused. Additionally, all 
samples were collected by two designated persons to ensure technical reproducibility and 







5.2 Placental gene expression in parturition 
The molecular mechanisms regulating the duration of pregnancy and initiation of labor are 
still incompletely understood. Clearly, interactions of maternal, placental, fetal and 
environmental factors cooperate in order to activate the uterus in order to expel the fetus 
(Challis et al., 2000b). Deregulation of these factors might cause premature delivery 
(Goldenberg et al., 2008). Moreover, there is epidemiological evidence that genetic factors 
might play a role in preterm birth (Varner and Esplin, 2005), indicating that regulation of 
gene expression in feto-maternal tissues may be involved in the process of parturition. Indeed, 
several studies using high-throughput methods (i.e. genomics, trancriptomics, proteomics) 
identified genes involved in prostaglandin synthesis and inflammatory response being 
differentially expressed in the myometrium, cervix and chorio-amniotic membranes in 
laboring compared to non-laboring women (Romero et al., 2006). However, few genomic 
studies have focused on the role of the human placenta in labor. A recent microarray study on 
placental tissue collected from five laboring and five non-laboring women, using only one 
array and indirect design, showed that most placental genes were not differentially expressed 
in labor and that a slightly (mean ratio=2.71) increased expression of matrix 
metalloproteinase-1 (MMP-1) was seen in laboring women (Vu et al., 2008). Another study 
using two 15K, custom-made human cDNA arrays on placental samples from seven women 
undergoing labor longer than 15 hours and 10 samples from women undergoing elective 
cesarean section, showed 90 transcripts to be significantly altered in their expression levels by 
>1.35-fold. Many of the placental genes up-regulated in women with prolonged labor were 
involved in oxidative stress (Cindrova-Davies et al., 2007). In our study, Placental FOS was 
the only gene that was down-regulated (2.2-fold) in women who delivered vaginally 
following normal (not prolonged) labor. Interestingly, in the study by Cindrova-Davies et al. 
(2007) placental FOS was 4.96-fold up-regulated in women with prolonged labor but the 
confidence interval of the CT values in RT-PCR were wide [6.72 (5.03-7.42) in non-laboring 
and 4.70 (2.96-6.93) in women after long labor]. However, ingenuity pathway analysis 
showed that FOS might play a role in the regulatory relationships among differentially 
expressed transcripts during labor.  
Results of our study indicate that placental gene expression profile is not significantly 
altered by normal labor. The discrepancies between our study and other studies (Cindrova-
Davies et al., 2007; Vu et al., 2008) might be due to different sample size, experimental 
design and image and data analysis criteria. We have used a larger sample size, direct 




previous studies. Uterine contractions cause intermittent reduction of blood flow to the uterus 
that might result in oxidative stress during prolonged labor. In our study, however, there were 
no significant hemodynamic differences in placental circulation. Moreover, the fetal oxygen 
uptake is not altered by normal labor (Acharya and Sitras, 2009). Our results support the 
assumption that the fetal genome and the maternal tissues play a key role in parturition, rather 
than the placenta (Challis et al., 2000a; Young, 2007). Nevertheless, it would be wise to 
balance between laboring and non-laboring women while matching subjects in comparative 
placental genomic studies. 
 
5.3 Placental gene expression in pregnancy disorders 
There is clinical, epidemiological, genetic and histopathologic evidence that abnormal 
placentation plays an important role in the pathogenesis of various pregnancy disorders, such 
as preeclampsia, IUGR, preterm birth and miscarriage (Roberts and Hubel, 2008). The results 
of this thesis provide evidence, at the transcript and protein level, that placental gene 
expression profile is altered in pregnancies complicated by severe preeclampsia and IUGR 
due to placental insufficiency. Our results are in concordance with previous microarray 
studies that consistently showed differential placental gene expression in preeclampsia 
(Founds et al., 2008; Enquobahrie et al., 2008) and IUGR (Roh et al., 2005; McMinn et al., 
2006), and we have made a comprehensive list of differentially expressed genes available 
(Paper II, Table 1S).  
A set of 16 genes was found to predict preeclampsia phenotype in the study samples 
and a set of 20 genes to separate IUGR from normal placentas. Some of these genes in 
combination with other biochemical and/or ultrasound markers (e.g. uterine artery Doppler, 
flow-mediated vasodilatation of brachial artery) might help in early identification of 
pregnancies at risk. In fact, some studies have already shown that the combined use of high 
maternal serum markers (e.g. hCG, sFlt1) and presence of notching in  the uterine artery wave 
form in mid trimester could predict preeclampsia and/or IUGR better (Hershkovitz et al., 
2005; Barkehall-Thomas et al., 2005; Stepan et al., 2007).  
Pathway analysis of differentially expressed genes showed angiogenesis, oxidative 
stress, Notch and Alzheimer disease signaling pathways to be involved in severe 
preeclampsia. Moreover, severe preeclampsia appeared to affect placental gene expression in 
different ways depending on the time of disease onset, with inflammation mediated by 
cytokines and chemokines pathway involved in early-onset disease. Interestingly, the same 




pathogenesis. Disturbance of placental development might cause preeclampsia phenotype in 
the mother and alter fetal programming (Myatt, 2006; Ness and Sibai, 2006). 
Investigation on how differentially expressed placental genes link together in the 
biological context, highlighted possible synergistic effects among hypoxia, oxidative stress, 
inflammation, apoptosis and folate metabolism in our study population. 6-
pyruvoyltetrahydropterin synthase (PTS), a key enzyme in the synthesis of tetrahydrobiopterin 
(H4B) and an essential cofactor of NO synthase, was significantly down-regulated in 
preeclamptic placentas. Placental H4B regulates NO synthase activity in late pregnancy 
(Kukor et al., 2000)  possibly through stabilization by vitamin C (Toth et al., 2002). 
Furthermore, H4B, folic acid, vitamin C and reactive oxygen species are known to interact in 
order to maintain adequate endothelial function (Figure 12) and thus unbalanced regulation 
might cause vascular diseases  (Das, 2003).  
 
 
Figure 12. Schematic representation of interaction between chemokines, vitamins, reactive oxygen species 
(ROS), nitric oxide (NO) and cyclooxygenases (COX) affecting endothelial function. Red arrows indicate 
negative and black arrows indicate positive effect 
 
Taken together these findings suggest that vitamins such as H4B, folic acid and 
vitamin C might have a role in the pathogenesis of preeclampsia. Indeed, there are ongoing 
clinical trials investigating the effect of vitamin and oxygen supplementation in the prevention 




trials have so far failed to prove a clear prophylactic and/or therapeutic effect of antioxidant 
therapy (Kontic-Vucinic et al., 2008), it must be underlined that these trials had different 
designs regarding participants, intervention schemes and outcomes.  
 
5.4 Placental angiogenesis in healthy and compromised pregnancies 
In the course of pregnancy there is a continuous regulation of placental villous vascular 
development. This process is not completely understood but it is thought to be controlled by 
the expression of several angiogenic growth factors, which is influenced by genetic, 
endocrine, metabolic and environmental factors (Charnock-Jones et al., 2004). Oxygen 
tension in the intervillous space is a major factor affecting the expression of these angiogenic 
factors, and hence, placental vasculo- and angio-genesis (Kaufmann et al., 2004). In fact, 
conditions causing fetal hypoxia might be regulated by placental angiogenic factors, including 
their receptors and antagonists (Mayhew et al., 2004). In our study population, the utero-
placental blood flow was reduced in preeclamptic pregnancies. This was reflected in placental 
gene expression profile with up-regulation of genes involved in angiogenesis, TGF-beta and 
VEGF signaling pathways in preeclamptic placentas. Recent studies suggest that an excess of 
placentally-derived anti-angiogenic factors (i.e. sFlt1 and ENG) in the maternal circulation 
might cause preeclampsia (Tjoa et al., 2007).  Levels of VEGF and its receptors (VEGFR1 
and 2) and PlGF are reported to be higher, lower or unaltered in late-onset preeclampsia and 
IUGR with positive end-diastolic flow in the umbilical arteries (Helske et al., 2001; Tse et al., 
2001). However, less evidence exists for the involvement of angiogenic factors in early-onset 
preeclampsia and IUGR with absent end-diastolic flow in the umbilical arteries (Khaliq et al., 
1999; Mayhew et al., 2004). Results of our studies suggest that the interpretation of the 
“angiogenic state” of the human placenta during preeclampsia and /or IUGR should be 
closely correlated to the phenotype of the disease, i.e. severity, time-onset and degree of 
hemodynamic compromise. 
 
5.5 Inflammatory pathways in early-onset preeclampsia and IUGR 
The placental genes involved in the inflammation mediated by cytokines and chemokines 
pathway were up-regulated in early-onset preeclampsia and IUGR in our study population.  
Cytokines include the interleukins, interferons and tumour necrosis factors (TNF) and have 
both pro- and anti-inflammatory actions (Jason et al., 2001). They play pivotal role in 
intercellular communication, especially between B- and T-cells, and affect neuronal, 




called also chemotactic cytokines, comprise a large family of small (6-14 kDa) proteins. They 
mediate their effects through binding with trans-membrane receptors on different leukocyte 
lineages with activation of G-protein signaling pathways (Mellado et al., 2001). The final 
effect is regulation of chemotaxis of immune cells and regulation of gene expression and 
apoptosis (Vlahakis et al., 2002).  
Maternal endothelial dysfunction during preeclampsia is linked to a generalized 
maternal inflammatory response (Redman et al., 1999). A pathophysiological model of 
preeclampsia where placental factors cause the clinical syndrome has been suggested 
(Redman and Sargent, 2005). Interactions among T-cells and placental cytokines and 
chemokines may alter maternal immune response and cause preeclampsia/IUGR (Visser et 
al., 2007). Results of our study show that the inflammation mediated by cytokines and 
chemokines pathway is altered in early-onset preeclampsia and IUGR, although it was not 
possible to match the gestational age of our patients with their controls. As normal pregnancy 
requires immune adaptation in the feto-placental interface, cytokine levels might change 
continuously throughout gestation, the validity of these results may be questioned. 
Nonetheless, cytokine-receptor microarray on placental samples (Pang and Xing, 2003) and 
serum cytokine (LEP, IL-10, TNF, IL-6 and IL-8) assay (Sharma et al., 2007) have also 
shown over-expression of inflammatory markers in preeclamptic women compared with 
gestational age matched healthy controls. Moreover, a microarray study of placental tissue 
obtained from two pregnancies complicated by early-onset preeclamptia with IUGR 
compared to a gestational age matched control placenta, showed up-regulation of 
inflammatory genes, many of which decode cytokines, in the absence of histopathologic 
inflammatory findings (Heikkila et al., 2005). 
 
5.6 Limitations and strengths of the studies 
Several approaches were used in order to optimize our experiments. We used direct 
comparison design which is more precise than the indirect design because the replicates 
available for comparison are doubled in number. Furthermore, it avoids the technical variation 
between the microarray slides caused by the instability of the common reference.  
Relatively large number (n=50) of “healthy” placentas (biological replicates) from 
women with uncomplicated pregnancies was collected in order to match them randomly with 
compromised placentas. Randomization is a crucial step in experimental design, performance 
and interpretation as it reduces both technical and biological variation in microarray 




true/causative, when randomization ensures that exposed and unexposed experimental units 
are interchangeable (Hernan and Robins, 2006). By randomizing, we were able to balance the 
possible confounding effects of maternal age, parity, fetal sex and delivery method between 
the study groups.  
The quality of mRNA was checked by electrophoresis and in study II 5 placentas that 
yield mRNA of poor quality even after repeated isolation were discarded. Poor mRNA quality 
may be due to apoptotic process that is shown to occur in the preeclamptic placenta (Allaire et 
al., 2000).  
 Microarrays are able to investigate gene expression only at a transcriptional level, i.e. 
measure the mRNA levels of a given gene at a given time. This has several drawbacks: (i) a 
single gene can give rise to multiple gene products (ii) RNA can be alternatively spliced or 
edited to form mature mRNA (iii) mRNA levels do not necessarily correlate with protein 
levels, which are the functional endpoints of coding genes (iv) proteins are regulated by 
additional mechanisms such as posttranslational modifications, compartmentalization and 
proteolysis (v) protein to protein interactions (folding) or cellular environmental conditions, 
such as pH and temperature, might affect protein function. Finally, biological function is 
determined by the complexity of these processes. All these factors are related to the 
functional, dynamic complexity of biological systems (such as cells, organs and organisms) 
which cannot be captured by microarrays. 
On the other hand, microarrays are a powerful tool of investigating genome-wide 
expression profile, providing information not otherwise attainable. Traditionally, biomedical 
research has been based on “reductionism” in the sense that complex biological systems were 
divided in simple units that were easier to explore and understand. However, as disease 
probably affects several molecular mechanisms, one can hypothesize that in certain diseases 
sets of genes are affected rather than a single gene. With the help of bioinformatic tools that 
analyze the relations among genes forming multiple molecular pathways, microarray 
technology provides insights into the mechanistic molecular processes occurring in the 
diseased cell/tissue as a whole. Another important related issue is the intercellular signaling, 
i.e. the interactions between the different cells in a tissue. These behavioral interactions 
between cells are difficult to explore in in vitro studies, making microarray comparison 
among diseased and healthy tissues a method that can point out the biological pathways 
involved in the development of the disease state.  Indeed, whole genome expression profiles 
have been successfully applied in cancer research aiming to classify different cancer subtypes 




types with different global gene expression profiles, may share common “genomic-related” 
response to therapy, individual metastasizing capabilities and different prognoses (Segal et al., 
2005). Moreover, signatures of differentially expressed sets of genes have been reproduced by 
several microarray platforms and laboratories, and validated in large patient populations using 
RT-PCR, indicating that results from microarray experiments can provide clinicians with 

































Genome-wide expression profiling of the placenta is a powerful tool to detect differences in 
gene expression between healthy and compromised pregnancies. From the results of this 
thesis, the following conclusions can be drawn: 
a. Placental gene expression is not significantly altered by normal labor, indicating a 
secondary role of this organ in the initiation and progression of normal parturition. 
b. Placental gene expression is profoundly altered in severe preeclampsia, 
suggesting that the placenta plays a central role in the pathogenesis of this disease. 
c. Placental angiogenic factors – including their receptors and antagonists – are 
involved in the pathogenesis of preeclampsia. However, the expression levels of 
placental angiogenic factors alone cannot clearly differentiate early- from late-
onset preeclampsia. 
d. There is no epigenetic modification of imprinted placental genes in placental 
insufficiency leading to IUGR. 
e. Inflammation mediated by cytokines and chemokines signaling pathway in the 
placenta might be involved in the development of early-onset preeclampsia and 
IUGR. 
 
7. FUTURE PERSPECTIVES 
Early-onset preeclampsia and IUGR due to placental insufficiency might share common 
placental pathogenesis. Preeclampsia and IUGR frequently lead to preterm delivery and are 
associated with poor perinatal outcome. Therefore, early identification of women at high risk 
of developing these complications might improve pregnancy outcome. A set of placental 
genes/proteins detected in the maternal blood and/or urine together with the assessment of 
maternal, fetal and placental hemodynamics might help clinicians in the prediction and early 
diagnosis of these pregnancy-specific disorders. In this respect, laeverin, a placenta specific 
protein that was found to be over-expressed in severe preeclampsia in our study population, 
deserves further investigation. In particular, it would be interesting to further explore the 
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